<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386721</url>
  </required_header>
  <id_info>
    <org_study_id>BP40234</org_study_id>
    <secondary_id>2017-003182-94</secondary_id>
    <nct_id>NCT03386721</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors</brief_title>
  <official_title>An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase II study to evaluate the antitumor activity of
      RO6874281 in combination with atezolizumab in participants with advanced and/or metastatic
      solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">March 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Baseline up to disease progression or study treatment discontinuation (assessed every 8 weeks after study treatment start, up to approximately 1 year)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disease Control According to RECIST Version 1.1</measure>
    <time_frame>Baseline up to disease progression or study treatment discontinuation (assessed every 8 weeks after study treatment start for the first year, and every 12 weeks thereafter, up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) According to RECIST Version 1.1</measure>
    <time_frame>From first occurrence of documented CR or PR up to disease progression or study treatment discontinuation (assessed every 8 weeks after study treatment start for the first year, and every 12 weeks thereafter, up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to RECIST Version 1.1</measure>
    <time_frame>Baseline up to disease progression or study treatment discontinuation (assessed every 8 weeks after study treatment start for the first year, and every 12 weeks thereafter, up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to death due to any cause (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Baseline up to end of the study (up to approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Programmed Death-Ligand 1 (PD-L1) Status According to Immunohistochemical Methods</measure>
    <time_frame>Baseline, Cycle 3 Day 8, Day 1 of Cycle 9 onwards up to end of the study (up to approximately 3 years) (1 cycle = 15 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Density of Cluster of Differentiation (CD) 8 Positive (CD8+) Cells According to Immunohistochemical Methods</measure>
    <time_frame>Day1 of Cycles 1, 2, 3, 6, and 9 onwards up to end of the study (up to approximately 3 years) (1 cycle = 15 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Density of Cluster of Differentiation 3 Negative (CD3-) Perforin Positive Cells According to Immunohistochemical Methods</measure>
    <time_frame>Day1 of Cycles 1, 2, 3, 6, and 9 onwards up to end of the study (up to approximately 3 years) (1 cycle = 15 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Density of PD-L1 According to Immunohistochemical Methods</measure>
    <time_frame>Baseline, Cycle 3 Day 8, Day 1 of Cycle 9 onwards up to end of the study (up to approximately 3 years) (1 cycle = 15 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Checkpoint Inhibitor (CPI)-Naïve Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have not received CPI therapy previously will receive RO6874281 intravenous (IV) infusion once in a week (QW) for first 4 doses, and once in 2 weeks (Q2W) for remaining doses up to maximum 24 months. Starting dose will be 15 milligrams (mg), and will be up-titrated to 20 mg from second administration onwards. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: collection of fresh tumor biopsies (at baseline and on-treatment) will be optional.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPI-Experienced Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have received CPI therapy previously will receive RO6874281 IV infusion QW for first 4 doses, and Q2W for remaining doses up to maximum 24 months. Starting dose will be 15 mg, and will be up-titrated to 20 mg from second administration onwards. Atezolizumab IV infusion will be administered in combination Q2W at a dose of 840 mg. Tumor biopsies: 2 mandatory fresh tumor biopsies, one at baseline and one on-treatment, will be collected. Additional on-treatment biopsies will be optional.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6874281</intervention_name>
    <description>RO6874281 will be administered as per the dosage regimen mentioned in arm descriptions.</description>
    <arm_group_label>Checkpoint Inhibitor (CPI)-Naïve Participants</arm_group_label>
    <arm_group_label>CPI-Experienced Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody</intervention_name>
    <description>Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.</description>
    <arm_group_label>Checkpoint Inhibitor (CPI)-Naïve Participants</arm_group_label>
    <arm_group_label>CPI-Experienced Participants</arm_group_label>
    <other_name>MPDL3280A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who have progressed on at least one previous regimen of anticancer
             therapy (chemotherapy, mutation targeted therapy, and/or CPI therapy)

          -  Measurable disease, as defined by RECIST Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 or Karnofsky
             Performance Score greater than or equal to (&gt;=) 70

          -  Life expectancy of &gt;=12 weeks

          -  Confirmed at least one tumor lesion with location accessible to safely biopsy per
             clinical judgment of the treating physician (not applicable to Part 1 Cohort A)

          -  Consent to provide an archival tumor tissue sample (if available, applicable to all
             participants)

          -  Willingness to undergo baseline and on-treatment tumor biopsies for pharmacodynamics
             (PD) biomarker analysis (not applicable to Part 1 Cohort A)

          -  Adequate cardiovascular function as defined in the study protocol

          -  AEs related to any previous radiotherapy, chemotherapy, or surgical procedure must
             have resolved to Grade less than or equal to (&lt;=) 1, except alopecia (any grade) and
             Grade 2 peripheral neuropathy

          -  Adequate haematological, liver, and renal functions

          -  Participants with unilateral pleural effusion are eligible if they fulfill both of the
             following: (a) New York Heart Association (NYHA) Class 1; (b) Global initiative for
             obstructive lung disease test level 1 (forced expiratory volume 1 / forced vital
             capacity less than [&lt;] 0.7 and forced expiratory volume &gt;=80 percent [%] predicted)

          -  Participants with Gilbert's syndrome will be eligible for the study

        CPI-Naïve Participants (Part 1 Cohort A):

          -  Participants must not have received CPI therapy (for example, anti- cytotoxic
             T-lymphocyte-associated protein 4 [anti-CTLA-4], anti-programmed death-1 [anti-PD-1]/
             anti-PD-L1) before study enrollment

          -  Participant must have progressed on at least one previous systemic therapy for
             advanced or metastatic disease

          -  Participants may be enrolled if they are ineligible for standard of care (SoC) therapy
             or if they are not willing to receive conventional therapy

          -  Participants whose tumors have a known sensitizing mutation (for example, Epidermal
             growth factor receptor [EGFR], Anaplastic Lymphoma Kinase [ALK] etc.) must have
             experienced disease progression (during or after treatment) or intolerance to
             treatment with a respective targeted therapy

        CPI-Experienced Participants (Part 1 Cohort B):

          -  Participants must have experienced documented disease progression on or after CPI
             therapy (investigational or approved)

          -  The CPI may have been administered as monotherapy or as part of a combination regimen
             at any time during the anti-cancer treatment before study enrollment

          -  Participants with suspected or documented disease progression within the first 12
             weeks of CPI therapy may not be eligible and require discussion with the Sponsor.
             Screening tumor assessment should confirm previous progression

          -  No history of severe immune-related adverse effects from CPI treatment (National
             Cancer Institute Common Terminology Criteria for AEs [NCI CTCAE] Grade 3 and 4)

        Exclusion Criteria:

          -  Symptomatic or untreated central nervous system (CNS) metastases

          -  History of treated asymptomatic CNS metastases as described in the protocol

          -  Spinal cord compression not definitively treated with surgery and/or radiation or
             previously diagnosed and treated spinal cord compression without evidence that disease
             has been clinically stable for &gt;=2 weeks before enrollment

          -  Leptomeningeal disease

          -  An active second malignancy

          -  Evidence of significant, uncontrolled concomitant diseases that could affect
             compliance with the protocol or interpretation of results

          -  Episode of significant cardiovascular/cerebrovascular acute disease within 6 months
             before study treatment administration

          -  History of significant vascular disease (for example, aortic aneurysm, aortic
             dissection)

          -  Peripheral arterial thrombosis within 6 months before study treatment administration

          -  Active or uncontrolled infections

          -  Human immunodeficiency virus (HIV) or hepatitis B or hepatitis C virus infection

          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
             (excluding fungal infections of nail beds) or any major episode of infection requiring
             treatment with IV antibiotics or hospitalization within 4 weeks before study treatment
             administration

          -  History of chronic liver disease or evidence of hepatic cirrhosis

          -  Serious, non-healing wound; active ulcer; or untreated bone fracture

          -  Dementia or altered mental status that would prohibit informed consent

          -  History of, active or suspicion of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced),
             organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia,
             etc.), or evidence of active pneumonitis on screening chest computed tomography (CT)
             scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted

          -  Bilateral pleural effusion confirmed by X-ray

          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that give reasonable suspicion of a disease or condition that would
             contraindicate the use of an investigational drug

          -  Concurrent therapy with any other investigational drug

          -  Immunomodulating agents as described in study protocol

          -  Chronic use of steroids

          -  Radiotherapy within the last 4 weeks before start of study treatment administration,
             with the exception of limited field palliative radiotherapy

          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1 or at
             any time during the study and 5 months after the last dose of atezolizumab

          -  Major surgery or significant traumatic injury &lt;28 days before study treatment
             administration (excluding fine needle biopsies) or anticipation of the need for major
             surgery during study treatment

          -  Known hypersensitivity to any of the components of the RO6874281 drug product or
             atezolizumab drug product

          -  Severe dyspnea at rest or requiring supplementary oxygen therapy

        CPI-Naïve Participants Only (Part 1 Cohort A):

        - Previous CPI therapy (for example, anti-CTLA-4, anti-PD-1/L1)

        CPI-Experienced Participants Only (Part 1 Cohort B):

          -  Participants who discontinued CPI therapy for CPI-associated toxicity or
             intolerability

          -  Any history of an immune-related Grade &gt;=3 AE attributed to previous cancer
             immunotherapy (with the exception of endocrinopathy managed with replacement therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP40234 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital; Clinical Oncology</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Hospital; National University Cancer Institute, Singapore (NCIS)</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre; Medical Oncology</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid. Centro Integral Oncologico Clara Campal; CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung Uni Hospital; Dept of Hematology and Oncology</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan Uni Hospital; Dept of Oncology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Nhs Trust; Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M2O 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

